Molecular Biology of Head and Neck Cancer: Risks and Pathways

Hematology/Oncology Clinics of North America

Volumn 22, Issue 6, 2008, Pages 1099-1124

  Stadler, Michael E ^a   Patel, Mihir R ^a   Couch, Marion E ^a,b   Hayes, David Neil ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cancer; Head and neck neoplasms; Molecular biology; Pathway; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIBW 2992; BORTEZOMIB; CCL 779; CEDIRANIB; CETUXIMAB; DASATINIB; ERLOTINIB; GEFITINIB; HUMAX EGFR; IMATINIB; LAPATINIB; LONAFARNIB; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NVP AEW 541; PANITUMUMAB; PAZOPANIB; PERIFOSINE; RAPAMYCIN; ROMIDEPSIN; SEMAXANIB; SERASAR; SOMATOMEDIN C RECEPTOR; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; TOVOK; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; VORINOSTAT; XL 880; ZALUTUMUMAB;

CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA MODIFICATION; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; MOLECULAR BIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA; VIRUS INFECTION;

EPIGENESIS, GENETIC; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS, SQUAMOUS CELL; RISK FACTORS;

EID: 55849150238     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.08.007     Document Type: Review

References (173)

1. Brennan J.A., Boyle J.O., Koch W.M., et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332 11 (1995) 712-717
2. Zain R.B., Gupta P.C., Warnakulasuriya S., et al. Oral lesions associated with betel quid and tobacco chewing habits. Oral Dis 3 3 (1997) 204-205
3. Norton S.A. Betel: consumption and consequences. J Am Acad Dermatol 38 1 (1998) 81-88
4. Warnakulasuriya S., Trivedy C., and Peters T.J. Areca nut use: an independent risk factor for oral cancer. BMJ 324 7341 (2002) 799-800
5. Lu C.T., Yen Y.Y., Ho C.S., et al. A case-control study of oral cancer in Changhua County, Taiwan. J Oral Pathol Med 25 5 (1996) 245-248
6. Denissenko M.F., Pao A., Tang M., et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274 5286 (1996) 430-432
7. Wilson III D.M., and Bohr V.A. The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst) 6 4 (2007) 544-559
8. Hung R.J., Hall J., Brennan P., et al. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 162 10 (2005) 925-942
9. Li C., Hu Z., Lu J., et al. Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. Cancer 110 4 (2007) 867-875
10. Cheng L., Sturgis E.M., Eicher S.A., et al. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer 94 2 (2002) 393-397
11. Handra-Luca A., Hernandez J., Mountzios G., et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13 13 (2007) 3855-3859
12. Shen M.R., Jones I.M., and Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58 4 (1998) 604-608
13. Lunn R.M., Helzlsouer K.J., Parshad R., et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21 4 (2000) 551-555
14. Duell E.J., Wiencke J.K., Cheng T.J., et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21 5 (2000) 965-971
15. Lunn R.M., Langlois R.G., Hsieh L.L., et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59 11 (1999) 2557-2561
16. Lei Y.C., Hwang S.J., Chang C.C., et al. Effects on sister chromatid exchange frequency of polymorphisms in DNA repair gene XRCC1 in smokers. Mutat Res 519 1-2 (2002) 93-101
17. Johnston L.D., and O'Malley P.M. The recanting of earlier reported drug use by young adults. NIDA Res Monogr 167 (1997) 59-80
18. Tashkin D.P. Pulmonary complications of smoked substance abuse. West J Med 152 5 (1990) 525-530
19. Tashkin D.P. Is frequent marijuana smoking harmful to health?. West J Med 158 6 (1993) 635-637
20. Hashibe M., Ford D.E., and Zhang Z.F. Marijuana smoking and head and neck cancer. J Clin Pharmacol 42 11 Suppl (2002) 103S-107S
21. Zhang Z.F., Morgenstern H., Spitz M.R., et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 8 12 (1999) 1071-1078
22. Donald P.J. Marijuana smoking-possible cause of head and neck carcinoma in young patients. Otolaryngol Head Neck Surg 94 4 (1986) 517-521
23. Zimmerman S., and Zimmerman A.M. Genetic effects of marijuana. Int J Addict 25 1A (1990) 19-33
24. Rosenblatt K.A., Daling J.R., Chen C., et al. Marijuana use and risk of oral squamous cell carcinoma. Cancer Res 64 11 (2004) 4049-4054
25. Lustig J.P., Lugassy G., Neder A., et al. Head and neck carcinoma in Fanconi's anaemia-report of a case and review of the literature. Eur J Cancer B Oral Oncol 31B 1 (1995) 68-72
26. Prime S.S., Thakker N.S., Pring M., et al. A review of inherited cancer syndromes and their relevance to oral squamous cell carcinoma. Oral Oncol 37 1 (2001) 1-16
27. Hecht F., and Hecht B.K. Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogenet 46 1 (1990) 9-19
28. Keukens F., van Voorst Vader P.C., Panders A.K., et al. Xeroderma pigmentosum: squamous cell carcinoma of the tongue. Acta Derm Venereol 69 6 (1989) 530-531
29. Cohen E.E., Rosen L.S., Vokes E.E., et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008)
30. Wells Jr. S.A., GJ, Gagel R.F., et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 25 (2007) 303s
31. Gillison M.L. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck 29 8 (2007) 779-792
32. Canto M.T., and Devesa S.S. Oral cavity and pharynx cancer incidence rates in the United States, 1975-1998. Oral Oncol 38 6 (2002) 610-617
33. Shiboski C.H., Schmidt B.L., and Jordan R.C. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 103 9 (2005) 1843-1849
34. Schantz S.P., and Yu G.P. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg 128 3 (2002) 268-274
35. Chaturvedi A.K., Engels E.A., Anderson W.F., et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26 4 (2008) 612-619
36. Syrjanen S. HPV infections and tonsillar carcinoma. J Clin Pathol 57 5 (2004) 449-455
37. Woods K.V., Shillitoe E.J., Spitz M.R., et al. Analysis of human papillomavirus DNA in oral squamous cell carcinomas. J Oral Pathol Med 22 3 (1993) 101-108
38. Mork J., Lie A.K., Glattre E., et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344 15 (2001) 1125-1131
39. Miller C.S., and Johnstone B.M. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91 6 (2001) 622-635
40. Luo C.W., Roan C.H., and Liu C.J. Human papillomaviruses in oral squamous cell carcinoma and pre-cancerous lesions detected by PCR-based gene-chip array. Int J Oral Maxillofac Surg 36 2 (2007) 153-158
41. Herrero R., Castellsague X., Pawlita M., et al. Human papillomavirus and oral cancer: the International agency for research on cancer multicenter study. J Natl Cancer Inst 95 23 (2003) 1772-1783
42. Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 9 (2000) 709-720
43. El-Mofty S.K., and Patil S. Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101 3 (2006) 339-345
44. Ragin C.C., Modugno F., and Gollin S.M. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 86 2 (2007) 104-114
45. Kreimer A.R., Clifford G.M., Snijders P.J., et al. HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. Int J Cancer 115 2 (2005) 329-332
46. Klussmann J.P., Weissenborn S.J., Wieland U., et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 92 11 (2001) 2875-2884
47. D'Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356 19 (2007) 1944-1956
48. Gillison M.L., D'Souza G., Westra W., et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100 6 (2008) 407-420
49. Califano J., van der Riet P., Westra W., et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56 11 (1996) 2488-2492
50. Tran N., Rose B.R., and O'Brien C.J. Role of human papillomavirus in the etiology of head and neck cancer. Head Neck 29 1 (2007) 64-70
51. Slebos R.J., Yi Y., Ely K., et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12 3 Pt 1 (2006) 701-709
52. Ansari-Lari M.A., Staebler A., Zaino R.J., et al. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 28 2 (2004) 160-167
53. Zhang M.Q., El-Mofty S.K., and Davila R.M. Detection of human papillomavirus-related squamous cell carcinoma cytologically and by in situ hybridization in fine-needle aspiration biopsies of cervical metastasis: a tool for identifying the site of an occult head and neck primary. Cancer 114 2 (2008) 118-123
54. Kreimer A.R., Clifford G.M., Boyle P., et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14 2 (2005) 467-475
55. Fakhry C., and Gillison M.L. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24 17 (2006) 2606-2611
56. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 5 (1990) 759-767
57. Weinberg R. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49 (1989) 3713-3721
58. Argiris A., Karamouzis M.V., Raben D., et al. Head and neck cancer. Lancet 371 9625 (2008) 1695-1709
59. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
60. Slaughter D.P., Southwick H.W., and Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6 5 (1953) 963-968
61. Sidransky D., Mikkelsen T., Schwechheimer K., et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355 6363 (1992) 846-847
62. Bedi G.C., Westra W.H., Gabrielson E., et al. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 56 11 (1996) 2484-2487
63. Hugo H., Ackland M.L., Blick T., et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213 2 (2007) 374-383
64. Moustakas A., and Heldin C.H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98 10 (2007) 1512-1520
65. Mani S.A., Guo W., Liao M.J., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 4 (2008) 704-715
66. Chung C.H., Parker J.S., Ely K., et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66 16 (2006) 8210-8218
67. Worsham M.J., Chen K.M., Meduri V., et al. Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132 6 (2006) 668-677
68. Thariat J., Milas L., and Ang K.K. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 69 4 (2007) 974-984
69. Citri A., and Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7 7 (2006) 505-516
70. Kalyankrishna S., and Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24 17 (2006) 2666-2672
71. Ciardiello F., and Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 358 11 (2008) 1160-1174
72. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 5 (2004) 785-794
73. Grandis J.R., and Tweardy D.J. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl 17F (1993) 188-191
74. Takes R.P., Baatenburg de Jong R.J., Schuuring E., et al. Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer Res 18 6B (1998) 4793-4800
75. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 24 (2002) 7350-7356
76. Kim S., Grandis J.R., Rinaldo A., et al. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 30 5 (2008) 667-674
77. Ford A.C., and Grandis J.R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25 1 (2003) 67-73
78. Lothaire P, de Azambiya E, Dequanter D, et al. Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation Head Neck 2006;28(3):256-69.
79. Reuter C.W., Morgan M.A., and Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96 3 (2007) 408-416
80. Sok J.C., Coppeti F.M., Thomas S.M., et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12 17 (2006) 5064-5073
81. Karamouzis M.V., Grandis J.R., and Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. J Am Med Assoc 298 1 (2007) 70-82
82. Akimoto T., Hunter N.R., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5 10 (1999) 2884-2890
83. Liang K., Ang K.K., Milas L., et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57 1 (2003) 246-254
84. Schmidt-Ullrich R.K., Valerie K.C., Chan W., et al. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys 29 4 (1994) 813-819
85. Schmidt-Ullrich R.K., Contessa J.N., Lammering G., et al. ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22 37 (2003) 5855-5865
86. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
87. Clinical trials.gov [cited 2007 September 21]. Available at:. http://www.clinicaltrials.gov/ Accessed April 28, 2008
88. Burtness B., Goldwasser M.A., Flood W., et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol 23 34 (2005) 8646-8654
89. Soulieres D., Senzer N.N., Vokes E.E., et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 1 (2004) 77-85
90. Eriksen J.G., Steiniche T., Askaa J., et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 58 2 (2004) 561-566
91. Bentzen S.M., Atasoy B.M., Daley F.M., et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23 24 (2005) 5560-5567
92. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 4 7 (2004) 505-518
93. Mitsiades C.S., and Mitsiades N. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther 5 3 (2005) 487-499
94. Larsson O., Girnita A., and Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92 12 (2005) 2097-2101
95. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21 3 (2000) 215-244
96. Baxter R.C. The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia. Horm Res 46 4-5 (1996) 195-201
97. Resnicoff M., Abraham D., Yutanawiboonchai W., et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55 11 (1995) 2463-2469
98. DeAngelis T., Ferber A., and Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J Cell Physiol 164 1 (1995) 214-221
99. Sell C., Dumenil G., Deveaud C., et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14 6 (1994) 3604-3612
100. Resnicoff M., Ambrose D., Coppola D., et al. Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest 69 6 (1993) 756-760
101. Trojan J., Johnson T.R., Rudin S.D., et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 259 5091 (1993) 94-97
102. Sell C., Rubini M., Rubin R., et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 90 23 (1993) 11217-11221
103. Reinmuth N., Fan F., Liu W., et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82 10 (2002) 1377-1389
104. Zeng H., Datta K., Neid M., et al. Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 302 1 (2003) 46-55
105. Zhang X., Lin M., van Golen K.L., et al. Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration. Breast Cancer Res Treat 93 2 (2005) 159-168
106. Long L., Rubin R., Baserga R., et al. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 55 5 (1995) 1006-1009
107. Zeigler M.E., Dutcheshen N.T., Gibbs D.F., et al. Growth factor-induced epidermal invasion of the dermis in human skin organ culture: expression and role of matrix metalloproteinases. Invasion Metastasis 16 1 (1996) 11-18
108. Goel H.L., Breen M., Zhang J., et al. Beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts. Cancer Res 65 15 (2005) 6692-6700
109. Abe S., Funato T., Takahashi S., et al. Increased expression of insulin-like growth factor I is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 209 3 (2006) 217-228
110. Allen G.W., Saba C., Armstrong E.A., et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67 3 (2007) 1155-1162
111. Camirand A., Lu Y., and Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8 12 (2002) BR521-BR526
112. Desbois-Mouthon C., Cacheux W., Blivet-Van Eggelpoel M.J., et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119 11 (2006) 2557-2566
113. Gee J.M., Robertson J.F., Gutteridge E., et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12 Suppl 1 (2005) S99-S111
114. Knowlden J.M., Hutcheson I.R., Barrow D., et al. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 146 11 (2005) 4609-4618
115. Wan X., and Helman L.J. Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia 4 5 (2002) 400-408
116. Wiseman L.R., Johnson M.D., Wakeling A.E., et al. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 29A 16 (1993) 2256-2264
117. Yin D., Tamaki N., Parent A.D., et al. Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Neurol Res 27 1 (2005) 27-35
118. Ouban A., Muraca P., Yeatman T., et al. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34 8 (2003) 803-808
119. Jones H.E., Goddard L., Gee J.M., et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11 4 (2004) 793-814
120. Ueda S., Hatsuse K., Tsuda H., et al. Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol 19 6 (2006) 788-796
121. Chakravarti A., Loeffler J.S., and Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62 1 (2002) 200-207
122. Tao Y., Pinzi V., Bourhis J., et al. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 4 10 (2007) 591-602
123. Barnes C.J., Ohshiro K., Rayala S.K., et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13 14 (2007) 4291-4299
124. Slomiany M.G., Black L.A., Kibbey M.M., et al. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett 248 2 (2007) 269-279
125. Riedemann J., and Macaulay V.M. IGF1R signalling and its inhibition. Endocr Relat Cancer 13 Suppl. 1 (2006) S33-S43
126. Garcia-Echeverria C., Pearson M.A., Marti A., et al. In vivo antitumor activity of NVP-AEW541-a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 3 (2004) 231-239
127. Brazil D.P., Yang Z.Z., and Hemmings B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29 5 (2004) 233-242
128. Kada F., Saji M., and Ringel M.D. Akt: a potential target for thyroid cancer therapy. Curr Drug Targets Immune Endocr Metabol Disord 4 3 (2004) 181-185
129. Bussink J., van der Kogel A.J., and Kaanders J.H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 9 3 (2008) 288-296
130. P O., Rhys-Evans P., Modjtahedi H., et al. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 18 2 (2000) 155-161
131. Vokes E.E., Cohen E.E., Mauer A.M., et al. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol 23 (2005) 5504
132. Massarelli E., Liu D.D., Lee J.J., et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104 11 (2005) 2430-2436
133. Amornphimoltham P., Sriuranpong V., Patel V., et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 10 12 Pt 1 (2004) 4029-4037
134. Molinolo A.A., Hewitt S.M., Amornphimoltham P., et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13 17 (2007) 4964-4973
135. Lim J., Kim J.H., Paeng J.Y., et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 58 11 (2005) 1199-1205
136. Kim D, Dan HC, Park S, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005;10:975-87.
137. Karamouzis MV F.D., Johnson R., et al. Phase II trial of pemetrexed (P) and bevacizumab (B) in patients with recurrent metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis. [abstract]. J Clin Oncol 25 (2007) 6049
138. Williamson S., Moon J., Huang C.H., et al. A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squmaous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial. J Clin Oncol 25 (2007) 3766-3773
139. Amornphimoltham P., Sodhi A., Patel V., et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65 21 (2005) 9953-9961
140. Elser C., Siu L.L., Winquist E., et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25 24 (2007) 3766-3773
141. Wendel H.G., De Stanchina E., Fridman J.S., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 6980 (2004) 332-337
142. Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98 18 (2001) 10314-10319
143. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22 14 (2004) 2954-2963
144. Nathan C.O., Franklin S., Abreo F.W., et al. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 17 9 (1999) 2909-2914
145. Nathan C.O., Amirghahari N., Rong X., et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 67 5 (2007) 2160-2168
146. Nathan C.O., Amirghahari N., Abreo F., et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 10 17 (2004) 5820-5827
147. Dong G., Chen Z., Kato T., et al. The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 59 14 (1999) 3495-3504
148. Loercher A., Lee T.L., Ricker J.L., et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64 18 (2004) 6511-6523
149. Chen Z., Malhotra P.S., Thomas G.R., et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5 6 (1999) 1369-1379
150. Ondrey F.G., Dong G., Sunwoo J., et al. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 26 2 (1999) 119-129
151. Zhang P.L., Pellitteri P.K., Law A., et al. Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 18 7 (2005) 924-932
152. Dong G., Loukinova E., Chen Z., et al. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer Res 61 12 (2001) 4797-4808
153. Duan J., Friedman J., Nottingham L., et al. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 6 1 (2007) 37-50
154. Duffey D.C., Chen Z., Dong G., et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59 14 (1999) 3468-3474
155. Kato T., Duffey D.C., Ondrey F.G., et al. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB. Head Neck 22 8 (2000) 748-759
156. Van Waes C., Chang A.A., Lebowitz P.F., et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63 5 (2005) 1400-1412
157. Lee T.L., Yeh J., Friedman J., et al. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 122 9 (2008) 1987-1998
158. Wang C.Y., Cusack Jr. J.C., Liu R., et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5 4 (1999) 412-417
159. Li N., and Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci U S A 95 22 (1998) 13012-13017
160. Anto R.J., Mukhopadhyay A., Shishodia S., et al. Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis 23 9 (2002) 1511-1518
161. Lin S.C., Lu S.Y., Lee S.Y., et al. Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes. Int J Cancer 116 4 (2005) 526-535
162. Allen C.T., Ricker J.L., Chen Z., et al. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 29 10 (2007) 959-971
163. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13 4 (2007) 1076-1082
164. Morimoto R.I., Kline M.P., Bimston D.N., et al. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem 32 (1997) 17-29
165. Stravopodis D.J., Margaritis L.H., and Voutsinas G.E. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem 14 29 (2007) 3122-3138
166. Ferrarini M., Heltai S., Zocchi M.R., et al. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51 4 (1992) 613-619
167. Solit D.B., and Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6 11 (2006) 1205-1214
168. Shintani S., Zhang T., Aslam A., et al. p53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines. Int J Oncol 29 5 (2006) 1111-1117
169. Yin X., Zhang H., Burrows F., et al. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 11 10 (2005) 3889-3896
170. Roepman P., Wessels L.F., Kettelarij N., et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 37 2 (2005) 182-186
171. Thomas G.R., Nadiminti H., and Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 86 6 (2005) 347-363
172. Chung C.H., Parker J.S., Karaca G., et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5 5 (2004) 489-500
173. Kumar B., Cordell K.G., Lee J.S., et al. EGFR, p16, HPV Titer, Bcl-xL